The FDA's launch of real-time clinical trial proof-of-concept studies signals a fundamental shift in regulatory oversight, one that most sponsors are not yet equipped to meet and that demands urgent investment in unified data infrastructure, quality-by-design practices, and protocol digitization.
The FDA's launch of proof-of-concept real-time clinical trials marks one of the most consequential shifts in regulatory oversight in decades. By enabling near real-time visibility into safety signals and endpoint data as trials progress, the agency is pushing the industry toward a continuous development model that most sponsors are not yet operationally equipped to support.
